Frost & Sullivan Publishes Update Coverage Report on DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.

February 6, 2018

Responsive image

Equity Research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program  
TEL AVIV, Israel, Feb. 6, 2018 /PRNewswire/ — The TASE analysis project was launched in 2016 in order to raise investors’ level of knowledge of TASE listed technology and biotec…

Category: Precious Metals